|$MATN & $GILD?????,6;41a.m. 07-07-2020 .M. Mateon Therapeutics Appts.||mick||07/28/20 6:25 PM|
|yes /\ Oncotelic Therapeutics Inc.||
|mick||11/21/22 10:35 AM|
|Charts don't matter.||John_Vallay||11/21/22 9:47 AM|
|http://www.stockta.com/cgi-bin/analysis.pl?symb=otlc||mick||10/23/22 3:27 PM|
|https://www.otcmarkets.com/stock/OTLC/security||mick||10/23/22 3:21 PM|
|#248 $MATN & $GILD?????,6;41a.m. 07-07-2020 .M. Mateon Therapeutics Appts. mick||mick||10/23/22 3:20 PM|
|OTLC Oncotelic Therapeutics Inc (QB)||mick||10/23/22 3:20 PM|
|Management is inept||John_Vallay||10/13/22 4:58 AM|
|OTLC Oncotelic Therapeutics Inc (QB)||mick||08/31/22 6:16 PM|
|OTLC Oncotelic Therapeutics Inc (QB)||mick||07/17/22 6:16 PM|
|Surprised at the lack of interest||i_like_bb_stock||06/20/22 4:51 PM|
|Looks like we should expect success in the||mishe||06/20/22 1:14 PM|
|Oncotelic Announces Pipeline Presentation and IPO Update of||mishe||06/15/22 4:42 PM|
|Oncotelic Therapeuti (OTLC)||mick||06/06/22 12:03 AM|
|nice news...https://www.otcmarkets.com/stock/OTLC/news/Oncotelic-Therapeutics-Re||i_like_bb_stock||05/25/22 9:11 AM|
|ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO||mishe||05/23/22 1:02 PM|
|Oncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief||mishe||05/04/22 12:55 PM|
|Oncotelic Appoints Seymour Fein M.D. as Chief Regulatory||mishe||05/04/22 12:54 PM|
|Oncotelic Therapeuti (OTLC)||mick||05/01/22 3:58 PM|
|$OTLC on watch due to Daily Chart increasing||PennyMaster||04/20/22 9:34 AM|
|$OTLC ONCOTELIC PROVIDES YE 2021 FINANCIAL RESULTS COMPARED||PennyMaster||04/19/22 11:18 AM|
|This Little Known Cancer Play has been Crushing||PennyMaster||04/14/22 9:49 AM|
|This Little Known Cancer Play has been Crushing||PennyMaster||04/14/22 9:49 AM|
|$OTLC Company Profile and Technical Chart Analysis||PennyMaster||04/13/22 10:12 AM|
|$OTLC The Accumulation here is off the charts||PennyMaster||04/12/22 9:39 AM|
|$OTLC Chart Forming Beautiful BULL FLAG here! Bullish||PennyMaster||04/11/22 9:16 AM|
|$OTLC Letter to Oncotelic Shareholders on the Recently||PennyMaster||04/08/22 9:42 AM|
|OTLC a bargain here, The JV will||i_like_bb_stock||04/07/22 11:27 AM|
|news https://www.globenewswire.com/news-release/2022/04/07/2418633/0/en/Letter-t||i_like_bb_stock||04/07/22 11:18 AM|
|Oncotelic; Announcing Successful Joint Venture and Diving into||mishe||04/04/22 2:31 PM|
|Oncotelic presentation at MedInvest Pharmaceutical & Biotechnology Investor||mishe||04/01/22 1:17 PM|
|Oncotelic JV Financing: https://www.youtube.com/watch?v=k0Zj59shmw0||mishe||03/21/22 3:44 PM|
|Oncotelic; Looking at Industry Comparison for the Company: https://www.youtube.c||mishe||03/15/22 4:40 PM|
|Oncotelic; Discussing the Company's Development Pipeline: https://www.youtube.c||mishe||03/15/22 3:51 PM|
|Oncotelic; Diving into the Company's Outlook for 2022: https://www.youtube.com/||mishe||03/15/22 3:40 PM|
|Oncotelic Therapeuti (OTLC)||mick||03/12/22 3:56 PM|
|Oncotelic to Present New Studies on its TGF-ß||mishe||03/10/22 1:45 PM|
|Questions: I did some DD and was||Justin Abreau||03/07/22 10:57 PM|
|Oncotelic; An Introduction to CFO Amit Shah &||mishe||03/02/22 5:54 PM|
|Oncotelic; An Introduction to CBO GM of AI||mishe||02/22/22 5:46 PM|
|Oncotelic; An Introduction to Chief Clinical Officer Anthony||mishe||02/22/22 5:45 PM|
|Oncotelic Therapeuti (OTLC)||mick||02/06/22 4:59 PM|
|Oncotelic Presenting at BiotechGate Digital Partnering: https://finance.yahoo.co||mishe||01/19/22 11:52 AM|
|$OTLC Oncotelic Initiates Phase 1 Trial Evaluating CA4P||TommyBoyTrader9460||01/11/22 1:45 PM|
|.19's starting to chip away now||Screech691||01/10/22 11:46 AM|
|Thinking the same..chart has been on the climb..||TommyBoyTrader9460||01/10/22 11:22 AM|
|wouldn't be surprised if it was a fake||Screech691||01/10/22 11:21 AM|
|$OTLC .19 up with a wall..watching for a||TommyBoyTrader9460||01/10/22 11:15 AM|
|looks like we've got the loading block at||Screech691||01/10/22 9:40 AM|
|$OTLC bidders at .18 now..continues to gain strength..||TommyBoyTrader9460||01/07/22 4:00 PM|
|agreed, just need that dumb seller at .19||Screech691||01/07/22 2:20 PM|
Oncotelic is actively seeking collaborations with corporations, academic institutions, and patient groups to advance our programs.
We have a history of successful partnerships and welcome new collaboration and licensing opportunities.
Through our history of collaborative research, Mateon has supported clinical research projects in the United Kingdom (UK) led by
Cancer Research UK (CRUK) along with additional academic partners.
Currently, we are supporting the PAZOFOS study (NCT02055690), which is being led by The Christie Hospital NHS Foundation Trust
and coordinated by the Manchester Academic Health Science Centre,
Trials Coordination Unit, or MAHSC-CTU, with additional support from The University of Manchester, the Royal Marsden NHS Foundation Trust,
and Mount Vernon Cancer Centre (part of the East and North Hertfordshire NHS Trust).
This Phase 1b/2 study is evaluating the combination of CA4P (fosbretabulin) with the tyrosine kinase inhibitor pazopanib (Votrient®) versus pazopanib
alone for the treatment of advanced recurrent ovarian cancer.
We are providing CA4P for use in this trial.
Continuing in our history of collaborative research, Mateon is providing investigational drug to the Markey Cancer Center for their study Study MCC-2016-08 (NCT03014297).
The study is designed as a single center, open label, phase 1 clinical trial for patients with grade 1-3 gastroenteropancreatic neuroendocrine tumors.
In the first part of the study, up to 15 patients will be treated with everolimus in combination with two different dosing regimens of
CA4P to establish appropriate CA4P dosing levels and evaluate the safety of the drug combination.
The second part of the study is designed to enroll 15 additional patients for assessment of additional safety and efficacy data.
Patients enrolled in MCC-2016-088 will be treated with CA4P and everolimus for 12 weeks.
We are committed to leveraging our intellectual property and the product development expertise of our highly experienced management team to enable
vascular targeted therapy to realize its true potential and to bring much needed new therapies for orphan oncology indications to cancer patients worldwide.
We have a portfolio of preclinical and clinical stage candidates focused on areas of significant unmet need that we believe can bring significant value to our shareholders.
Our common stock is traded on the OTCQB Market under the symbol “MATN”.
We are headquartered in Agoura Hills, California
EdgePoint AI was established in order to advance the company’s revolutionary cluster-computer platform for AI that processes machine learning
models at a fraction of the power and budget of mainstream computing in pharmaceutical manufacturing.
The company’s technology solution “TrustPoint” provides an AI computing platform for pharmaceutical and healthcare verticals
including blockchain support for manufacturing where data integrity and security are of utmost importance.
EdgePoint is composed of a team of executives with pharmaceutical drug development, GMP manufacturing and deep AI knowledge.
The team includes Steven King who was the former CEO of Peregrine Pharmaceuticals, Inc. (NASDAQ) and its wholly-owned
contract biomanufacturing subsidiary Avid Bioservices, Inc., for over 15 years, during which time the company advanced its
lead compound through Phase 3 development, while growing revenues to over $55 million;
Seasoned executive, Saran Saund who has been founder, CEO and GM at several startups and public companies for which he returned
significant value to shareholders in his startups and chief technology officer; Burcak Beser who has been founder and
CTO of several successful private and public companies with over 144 patents during his career; and Lisa Stepp with broad experience in
executive leadership across geographies and in all aspects of drug development and program management.
The core technology platform for EdgePoint AI came from PointR -which was acquired by Mateon in Nov 2019. Examples of PointR capabilities are shown below.
Health Care: Drug Developer Adds Digital Monitor
TWO YEAR CHART: NASDAQ
PER IHUB MGMT
DISCLAIMER: ONLY FOR MICK
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any